About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Our research group is focused on studying the pathophysiology of migraine and other primary headaches using preclinical, translational and clinical research.
Migraine will allow us to define the brain’s adaptive, sensory/cognitive functions, through genetics, epigenetics, neurophysiology, neuromolecular and neuroanatomical information with an interest in developing clinical therapeutic solutions, with the goal on having an impact on suffering and increasing the well-being.
PMID: 34030634 Journal: JOURNAL OF HEADACHE AND PAIN Year: 2021 Reference: J Headache Pain. 2021 May 24;22(1):43. doi: 10.1186/s10194-021-01258-y. Impact factor: 7.277 Publication type: Paper in international publication Authors: Gago-Veiga, A B, Huhn, J-I, Latysheva, N, Vieira Campos, A, Torres-Ferrus, M, Alpuente Ruiz, A, Sacco, S, Frattale, I, Ornello, R, Ruscheweyh, R et al. DOI: 10.1186/s10194-021-01258-y
PMID: 33867184 Journal: NEUROLOGIA Year: 2021 Reference: Neurologia (Engl Ed). 2021 Apr 15. pii: S0213-4853(21)00054-2. doi: 10.1016/j.nrl.2021.01.018. Impact factor: 3.109 Publication type: Paper in national publication Authors: Belvis, R, Santos-Lasaosa, S, Irimia, P, Lopez Blanco, R, Torres-Ferrus, M, Morollon, N, Lopez-Bravo, A, Garcia-Azorin, D, Minguez-Olaondo, A, Guerrero, A et al. DOI: 10.1016/j.nrl.2021.01.018
PMID: 33832802 Journal: NEUROLOGIA Year: 2021 Reference: Neurologia (Engl Ed). 2021 Mar 19. pii: S0213-4853(21)00056-6. doi: 10.1016/j.nrl.2021.03.003. Impact factor: 3.109 Publication type: Paper in national publication Authors: Caronna, E, Jose Gallardo, V, Alpuente, A, Torres-Ferrus, M, Sanchez-Mateo, N M, Viguera-Romero, J, Lopez-Veloso, A C, Lopez-Bravo, A, Gago-Veiga, A B, Irimia Sieira, P et al. DOI: 10.1016/j.nrl.2021.03.003
PMID: 33778933 Journal: Pain and Therapy Year: 2021 Reference: Pain Ther. 2021 Jun;10(1):637-650. doi: 10.1007/s40122-021-00253-0. Epub 2021 Mar 28. Impact factor: 5.725 Publication type: Paper in international publication Authors: Guerzoni, Simona, Ornello, Raffaele, Ahmed, Fayyaz, Negro, Andrea, Miscio, Anna Maria, Santoro, Antonio, Alpuente, Alicia, Russo, Antonio, Silvestro, Marcello, Cevoli, Sabina et al. DOI: 10.1007/s40122-021-00253-0
The treatment with fremanezumab becomes the first approved therapy to demonstrate efficacy in children and adolescents, a key stage of life as it is one of the most disabling and concentrates the peak incidence of the disease.
Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research
Two international studies led by Vall d'Hebron recommend early administration of specific drugs to prevent migraine to achieve a better response to therapy.
